# Evaluation of Circulating Tumor DNA as a Theranostic Marker in the Management of Glioblastomas.

> **NCT03115138** · NA · TERMINATED · sponsor: **Centre Hospitalier Universitaire, Amiens** · enrollment: 19 (actual)

## Conditions studied

- Glioblastoma
- Molecular Disease

## Interventions

- **OTHER:** Correlation between molecular anomalies of the primary tumor and circulating tumor DNA

## Key facts

- **NCT ID:** NCT03115138
- **Lead sponsor:** Centre Hospitalier Universitaire, Amiens
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-03-09
- **Primary completion:** 2017-11-06
- **Final completion:** 2017-11-06
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** investigator choice
- **Last updated:** 2020-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03115138

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03115138, "Evaluation of Circulating Tumor DNA as a Theranostic Marker in the Management of Glioblastomas.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03115138. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*